 Obalon Therapeutics, Inc. NASDAQ:OBLN, a vertically integrated weight loss solutions company commercializing the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, announces that it has temporarily suspended sales of its novel weight loss treatment to new patients at its existing retail treatment centers in San Diego and Orange County, California as a precaution against the spread of the coronavirus COVID-19. The retail treatment centers will continue to fully treat and care for patients already in treatment with the Obalon Balloon System, and non-essential personnel will work remotely. The safety, health and well-being of our patients, employees and providers remain our highest priority, therefore we are taking these steps to mitigate the impact of COVID-19 at Obalon retail facilities, said Bill Plovanic, President and Chief Executive Officer of Obalon. 